Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Resignation of Mr. Ronak Lalwani from the post of Company Secretary & Compliance Officer01-07-2021
01-07-2021
Earum Pharmaceuticals Ltd - 542724 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
In compliance to the Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 please find enclose herewith the Postal Ballot Notice Dated June 10, 2021 along with Explanatory Statement and Postal Ballot Form, seeking consent of the members by way of Special Resolutions and Ordinary Resolution by Postal ballot in respect of the resolution as set out in the Postal Ballot Notice. Further this is to inform that Company has completed the dispatch of Postal Ballot Notice along with Postal Ballot Form to the members as on cut-off date i.e. 11th June, 2021. You are requested to kindly take the same on record16-06-2021
Earum Pharmaceuticals Ltd - 542724 - Board recommends Bonus Issue
Earum Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 10, 2021, inter alia, have approved and recommended the issuance of fully paid up bonus shares in the ratio of 1:1 (i.e. 1 fully paid up share for every 1 fully paid up equity shares held, subject to the shareholders approval through postal ballot.10-06-2021
Earum Pharmaceuticals Ltd - 542724 - Board recommends Bonus Issue
Earum Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 10, 2021, inter alia, have approved and recommended the issuance of fully paid up bonus shares in the ratio of 1:1 (i.e. 1 fully paid up share for every 1 fully paid up equity shares held, subject to the shareholders approval through postal ballot.10-06-2021
Earum Pharmaceuticals Ltd - 542724 - Intimation Pursuant To Regulation 30 And 33 Of SEBI (Listing Obligation & Disclosure Requirements), Regulation 20L5 And Outcome Of Board Meeting
1. increase in authorised share capital of the company from existing Rs. 7,00,00,000 (Rupees Seven Crore) divided into 70,00,000 (Seventy Lakh) equity shares of Rs. 10/- each to Rs.12,35,00,000 (Rupees Twelve Crore Thirty Five Lakh) 2. issuance of fully paid up bonus shares in the ratio of 1:1 3. appoint Mr. Dahyabhai Mafatlal Patel as an additional director 4. 4. The Board approve the Audited financial results of the company for the financial year ended on 31st March, 2021 5. issuance of equity shares to the directors of the company on preferential basis against conversion of unsecured loans 6. Migration of company from BSE SME platform to Main board of BSE Limited 7. Appointment of M/s Shikha Patel & Associates, PCS as the scrutiniser for postal ballot process10-06-2021
Earum Pharmaceuticals Ltd - 542724 - Board to consider Bonus Issue
Earum Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company scheduled to be held on June 10, 2021, inter alia, to transact the following business:1. To consider and approve Increase in Authorised Share Capital of the Company.2. To consider and approve the Issue of Bonus Shares.3. To appoint Mr. Dahyabhai Mafatlal Patel as Additional Director of the Company.4. Approval of Audited Financial Results of the Company for the quarter and financial year ended on March 31, 2021.5. To consider an issuance of equity shares to the directors of the Company on preferential basis against the conversion of unsecured loans lying in the Company from directors.Further, as per the Company's code of conduct to regulate, monitor and report trading by insiders, adopted by the Board pursuant to SEBI (Prohibition of insider trading) Regulations, 2015, the trading window for dealing in the securities of the Company by the designated persons and their immediate relatives of the Company has already been closed from April 01, 2021 and shall remain closed till 48 hours from the closure of the Board Meeting.31-05-2021
Earum Pharmaceuticals Ltd - 542724 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company Scheduled To Be Held On 10Th June, 2021
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/06/2021 ,inter alia, to consider and approve We hereby inform you that, pursuant to Regulation 29 of the securities and Exchange board of India (Listing obligations and disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors of the company scheduled to be held on Thursday, 10th June, 2021 at 04:00 PM at the Corporate Office Of The Company Situated At A-1106, Empire Business Hub, Near Auda Water Tank, Science City Road, Sola, Ahmedabad, Gujarat - 380060, inter alia to transact the following business: 1. To consider and approve Increase in Authorised Share Capital of the Company. 2. To consider and approve the Issue of Bonus Shares. 3. To appoint Mr. Dahyabhai Mafatlal Patel as Additional Director of the Company. 4. Approval of Audited Financial Results of the Company for the quarter and financial year ended on March 31, 2021. 5. To consider an issuance of equity shares to the directors of the company on preferential basis against the conversion of unsecured loans lying in the company from directors.29-05-2021
Earum Pharmaceuticals Ltd - 542724 - Intimation Of Resignation Of Director
pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We wish to inform that Mr. Narendrakumar Gangaramdas Patel has resigned from the position of Director of the company with effective from 08th May 2021 due to the reason mentioned in his resignation letter dated 08th May 2021 (enclosed herewith). The Board at their meeting held on 8th May 2021 took on record the resignation of Mr. Narendrakumar Gangaramdas Patel and recorded its appreciation for the valuable services rendered by him during his tenure as a Director of the company. This is for information and record.08-05-2021
Earum Pharmaceuticals Ltd - 542724 - Compliance Certificate Under Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended On 31St March, 2021.
Pursuant to requirement of Regulation 7(3) of the Securities and exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that all activities in relation to both physical and electronic share transfer facility are maintained during the period Commencing from 01st October 2020 to 31st March, 2021 (both days inclusive) by our Share Transfer Agent viz. Bigshare Services Private Limited having Registration Number is INR000001385. Kindly take note of the above.20-04-2021
Earum Pharmaceuticals Ltd - 542724 - Compliance Certificate In Terms Of Regulation 40 (9) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended On March 31, 2021.
Pursuant to Regulation 40(10) of the Securities and exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a certificate Issued by PRO & Co., Company Secretaries for the half year ended on 31st March, 2021 in Compliance with Regulation 40(9) of the above mentioned Regulations. This is for your information and record.20-04-2021